U.S. Markets closed

Wired News – ArQule Inked Exclusive License Deal with Basilea for Derazantinib in the US, EU, Japan and Rest of World

Stock Monitor: Hemispherx Biopharma Post Earnings Reporting

LONDON, UK / ACCESSWIRE / April 19, 2018 / Active-Investors.com has just released a free research report on ArQule, Inc. (NASDAQ: ARQL). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ARQL as the Company's latest news hit the wire. On April 17, 2018, the Company announced on that it has signed an exclusive license deal with Switzerland-based Basilea Pharmaceutica International Ltd ("Basilea"), to develop and commercialize ArQule's oncology drug candidate, derazantinib, in the US, EU, Japan, and rest of the world excluding the People's Republic of China, Hong Kong, Macau, and Taiwan. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Hemispherx Biopharma, Inc. (NYSE AMER: HEB), which also belongs to the Healthcare sector as the Company ArQule. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=HEB

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, ArQule most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=ARQL

Terms of the Deal

  • Basilea will make an upfront payment of $10 million to ArQule and additional $326 million in regulatory and commercial milestones payments.
  • ArQule will also receive staggered single-digit to double-digit royalties on net sales upon commercialization.
  • Basilea will be responsible for all costs and expenses of development, manufacture, and commercialization in its territory. Under certain circumstances, ArQule may have the opportunity to promote derazantinib in the US directly.
  • ArQule is currently conducting a registrational trial for derazantinib in the United States, Canada, and Europe as a potential treatment for intrahepatic cholangiocarcinoma (iCCA), a form of biliary tract cancer. As part of the license agreement, Basilea intends to continue this trial and the further development of derazantinib in iCCA and other tumor types with FGFR dysregulation.

Derazantinib is an Ideal Match for Basilea's Existing Clinical Oncology Portfolio

Commenting on the agreement, Ronald Scott, Chief Executive Officer of Basilea, stated that Derazantinib is an ideal match for Basilea's existing clinical oncology portfolio. This transaction underscores Basilea's continued commitment to expand its R&D portfolio with novel compounds focused on overcoming the clinical problem of resistance in oncology and infectious diseases.

Ronald added that the Company's clinical oncology portfolio now includes three drug candidates in different stages of development.

Basilea will Bring a Wealth of Skills to the Expansion of the Derazantinib Development Plan

Paolo Pucci, Chief Executive Officer of ArQule, mentioned that partnering with Basilea, a company with global drug development experience and expertise, will propel the advancement of derazantinib in ways ArQule could not have achieved independently.

Paolo added that Basilea will bring a wealth of skills to the expansion of the derazantinib development plan at a time when it will benefit most from these resources, allowing it to reach its full potential in iCCA and beyond.

ArQule Out-Licenses Derazantinib to Roivant in China, Hong Kong, Macau, and Taiwan

On February 07, 2018, Roivant Sciences and ArQule announced the initiation of a collaboration to pursue the development of derazantinib in Greater China. As part of the collaboration, ArQule granted a Roivant subsidiary, Sinovant Sciences Ltd, an exclusive license to develop and commercialize derazantinib in the People's Republic of China, Hong Kong, Macau, and Taiwan.

About Derazantinib

Derazantinib (ARQ 087) is an investigational, oral, multi-kinase inhibitor designed to preferentially inhibit the FGFR family of kinases with demonstrated activity in FGFR2 genetic alterations, including fusions. The drug has demonstrated favorable clinical data in a biomarker-driven Phase-1/2 trial in iCCA targeting patients with FGFR2 fusions. Both the FDA and EMA have granted ArQule orphan drug designation for this disease.

About ArQule, Inc.

Founded in 1993 and headquartered in Burlington, Massachusetts, ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and certain rare diseases.

About Basilea Pharmaceutica International Ltd

Based in Basel, Switzerland, Basilea is a commercial stage biopharmaceutical company developing products that address the medical challenge of increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections, and cancer.

Stock Performance Snapshot

April 18, 2018 - At Wednesday's closing bell, ArQule's stock marginally dropped 0.95%, ending the trading session at $3.13.

Volume traded for the day: 4.79 million shares, which was above the 3-month average volume of 734.21 thousand shares.

Stock performance in the last month – up 34.91%; previous three-month period – up 81.98%; past twelve-month period – up 226.04%; and year-to-date - up 89.70%

After yesterday's close, ArQule's market cap was at $281.48 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was flat at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

  • The ‘smart money’ says it’s time to buy the Chinese internet giants and the U.S. FAANGs
    News
    MarketWatch

    The ‘smart money’ says it’s time to buy the Chinese internet giants and the U.S. FAANGs

    When the media and investors turn negative on stocks but the “smart money” is bullish, it’s a good time to think about buying. After all, exactly what is the smart money, and how do you know? Lately, several fund managers who pass this test have been pounding the table on Chinese internet names.

  • What happens if you win Mega Millions' $970M jackpot?
    News
    Associated Press

    What happens if you win Mega Millions' $970M jackpot?

    Despite the terrible odds — one in 302.5 million for those keeping score at home — someone will eventually match all six numbers and win the Mega Millions jackpot, which now stands at $970 million. Here are some answers for someone holding that prized lottery ticket for what would be the second-largest lottery jackpot in U.S. history. Lottery officials recommend winners take a deep breath, put their winning ticket in a safe spot and consult with a reputable financial planner before popping over to the lottery headquarters.

  • Qualcomm Asks 9th Circuit to Intervene in $5B Class Action
    Business
    ALM Media

    Qualcomm Asks 9th Circuit to Intervene in $5B Class Action

    Qualcomm is asking the U.S. Court of Appeals for the Ninth Circuit to intervene in the massive antitrust class action certified last month by U.S. District Judge Lucy Koh. Qualcomm argues in a petition filed Friday that Koh committed multiple errors, including depriving Qualcomm of a hearing before certifying a class of some 250 million cellphone purchasers. “The court’s analysis was deficient in process, reasoning, and result,” Qualcomm states in the petition, which is signed by Keker, Van Nest & Peters partner Robert Van Nest.

  • Finding a Cure for Kinder Morgan’s Frustration
    Business
    Bloomberg

    Finding a Cure for Kinder Morgan’s Frustration

    Rising profits – Ebitda was up 6 percent, year over year – and that Canadian pipeline sale have helped address Kinder Morgan’s biggest problem, its crushing debt. Thankfully, it provided a strong signal on Wednesday evening that it would.

  • Provocateur Stormy Daniels Takes an Unexpected Turn in the National Spotlight
    News
    Time

    Provocateur Stormy Daniels Takes an Unexpected Turn in the National Spotlight

    To understand what it means to be famous like Stormy Daniels, for the reasons she is famous, spend time with her in a public space. On Oct. 15, a California judge threw out the defamation case she filed against Donald Trump. Over the past year, Daniels, 39, has become the Zelig of White House scandals.

  • Here's everyone who has dropped out of Saudi Arabia's 'Davos of the Middle East'
    Finance
    Yahoo Finance

    Here's everyone who has dropped out of Saudi Arabia's 'Davos of the Middle East'

    U.S. Treasury Secretary Steven Mnuchin tweeted Thursday that he will not be attending the Future Investment Initiative in Saudi Arabia next week. The news comes after prominent members of the world’s business community have been dropping out of Saudi

  • Employee Accused of Urinating on Production Line at Food Processing Facility
    Business
    WTKR - Norfolk

    Employee Accused of Urinating on Production Line at Food Processing Facility

    Smithfield Foods, Inc. said in a statement Tuesday that it disposed of more than 50,000 pounds of product after reports of an employee urinating at his station at the company’s processing facility in Virginia.

  • The 1 Thing Investors Should Do Now That Canadian Marijuana Stocks Have Fallen
    Business
    Motley Fool

    The 1 Thing Investors Should Do Now That Canadian Marijuana Stocks Have Fallen

    Canada's highly anticipated recreational marijuana market opened on Wednesday. The three biggest Canadian marijuana producers by market cap -- Tilray (NASDAQ: TLRY), Canopy Growth (NYSE: CGC), and Aurora Cannabis (NASDAQOTH: ACBFF) -- saw their share prices fall by several percentage points. What should investors' response be after the blah performance for marijuana stocks on Wednesday?

  • Markets think the midterms could be as big as the presidential election
    Finance
    Yahoo Finance

    Markets think the midterms could be as big as the presidential election

    The midterm elections are less than three weeks away. According to strategists at Barclays, the options market is pricing in a 1.6% swing on election night, a modest swing given the recent volatility we’ve seen in the stock market.

  • 7 Stocks Warren Buffett Can’t Stop Buying
    Finance
    InvestorPlace

    7 Stocks Warren Buffett Can’t Stop Buying

    Sometimes identifying the best stocks to buy can be difficult, but you could do a lot worse than checking out the stocks selected by one of the world’s savviest hedge fund managers — Warren Buffett. Buffett’s stock picks are a popular source for investors, and for good reason. The billionaire Buffett is many things: He’s among the world’s most successful fund managers, a legendary philanthropist and owns more than 60 companies.

  • Business
    CNBC

    Goldman Sachs sees a correction coming for chipmakers but still likes Nvidia

    "We foresee a cyclical correction approaching and recommend investors to stay selective in Semis," Goldman Sachs said in a note Thursday. Nvidia is Goldman's top choice in the industry. Goldman Sachs warned clients about a downturn coming for the semiconductor sector, but still recommends some chip stocks.

  • Finance
    CNBC

    China's stock market is getting pummeled and history shows that is bad news for US markets

    U.S. stocks are lower about 70 percent of the time in periods when there are big drops of 10 percent or more in Shanghai stocks, according to analytics firm Kensho. The main U.S. indexes lose about 5 percent when Shanghai stocks fall 10 percent or more in a 30-day period. Big blue chips, like Goldman and Caterpillar are among the losers, but copper and oil also fall hard when Shanghai sees a big decline.

  • There’s a Huge Flaw in Valuing AMD Stock Like Amazon or Netflix
    Finance
    InvestorPlace

    There’s a Huge Flaw in Valuing AMD Stock Like Amazon or Netflix

    This year has been an undeniably good one for Advanced Micro Devices (NASDAQ:AMD) shareholders. The AMD stock price is up 165% year-to-date, and seems to be dealing with recent headwinds relatively well. Although the turnaround is real, the market’s valuation of AMD stock has been exceedingly generous.

  • Uber driver charged with kidnapping New York woman
    News
    Associated Press

    Uber driver charged with kidnapping New York woman

    An Uber driver in New York City kidnapped a woman who fell asleep in his vehicle, groped her in the back seat and then left her on the side of a highway in Connecticut, federal authorities said Tuesday. Harbir Parmar, 24, of Queens, was charged in U.S. District Court with kidnapping. "The presumption of innocence remains with my client," Parmar's lawyer, Susanne Brody, told The New York Times at the courthouse after the hearing.

  • Cramer: Buy FAANG now
    NFLX
    CNBC Videos

    Cramer: Buy FAANG now

    CNBC's 'Squawk on the Street' team discusses why Jim Cramer is bullish on FAANG stocks.

  • United Airlines Reports Another Quarter of Strong Earnings -- for United
    Business
    Motley Fool

    United Airlines Reports Another Quarter of Strong Earnings -- for United

    Over the past year or so, I've been rather skeptical about United Continental's (NYSE: UAL) plan to boost its earnings by accelerating its growth rate, particularly in smaller cities. Indeed, United Airlines released another strong earnings report on Tuesday afternoon and raised its full-year guidance for the third consecutive quarter. It now expects to post full-year adjusted earnings per share of $8.00 to $8.75 -- up from an initial guidance range of $6.50 to $8.50 -- even though it is on track to spend an extra $700 million on fuel compared to its original forecast.

  • Musk’s Big China Play Comes as World’s Top Car Market Slows
    Business
    Bloomberg

    Musk’s Big China Play Comes as World’s Top Car Market Slows

    Acquiring the parcel keeps Tesla on track to spend several billion dollars on its first overseas plant in the world’s largest electric-vehicle market. President Donald Trump’s trade war with China has led to higher Chinese tariffs on American imports, stoking concern about an economic slowdown. Tesla fell 1.7 percent to $271.78 in New York trading Wednesday.

  • Ford Motor Company Earnings: What to Watch For
    Business
    Motley Fool

    Ford Motor Company Earnings: What to Watch For

    Ford Motor Company (NYSE: F) will report its third-quarter earnings results after the markets close on Oct. 24. Wall Street analysts polled by Thomson Reuters expect Ford to report earnings of $0.30 per share, on average, down from $0.43 in the third quarter of 2017. Ford's F-Series pickups continue to sell well and generate good profits, thanks to high-margin versions like this F-150 Limited.

  • The same question that can chart a path to early retirement is the one Warren Buffett used to build Berkshire Hathaway into a powerhouse
    Business
    Business Insider

    The same question that can chart a path to early retirement is the one Warren Buffett used to build Berkshire Hathaway into a powerhouse

    Inversion is a mental model that involves flipping your outlook to prevent the opposite of what you want to happen from happening. Warren Buffett and his business partner Charlie Munger employed inversion as a business strategy to build Berkshire Hathaway into a powerhouse. In a recent podcast with Brandon of the Mad Fientist, who retired early at 34, productivity expert James Clear said the same strategy Buffett used can help set someone on the path for early retirement.

  • Pfizer’s Growth Rate and Estimates
    Finance
    Market Realist

    Pfizer’s Growth Rate and Estimates

    Pfizer's Stock Performance and Estimates in October (Continued from Prior Part) Pfizer’s revenues and EPS Pfizer (PFE) reported an EPS of $0.74 on revenues of ~$13.5 billion during the second quarter, which beat analysts’ estimate of ~$13.3 billion

  • Jamal Khashoggi's brutal death brings to question an era of Bay Area tech investment
    Finance
    American City Business Journals

    Jamal Khashoggi's brutal death brings to question an era of Bay Area tech investment

    New details have emerged about the killing of journalist Jamal Khashoggi by Saudi agents — involving his beheading and dismemberment upon entering the Saudi consulate in Istanbul, Turkey — thanks to audio files described by Turkish officials. As evidence mounts of the Washington Post columnist’s gruesome death tied to Saudi Arabia, Bay Area tech companies, which have gobbled up billions in funding from the kingdom in recent years, could see that money river dry up as Saudi investment becomes increasingly toxic. President Donald Trump has criticized those rushing to condemn the nation, telling the Associated Press: "You know, you’re guilty until proven innocent." Yet even still, Japanese investor Softbank isn’t stomaching the brutal killing tied to its major investment fund so easily.

  • Alibaba (BABA) Dips More Than Broader Markets: What You Should Know
    Finance
    Zacks

    Alibaba (BABA) Dips More Than Broader Markets: What You Should Know

    Investors will be hoping for strength from BABA as it approaches its next earnings release, which is expected to be November 2, 2018. On that day, BABA is projected to report earnings of $1.16 per share, which would represent a year-over-year decline of 10.08%. Investors should also note any recent changes to analyst estimates for BABA.

  • Kinder Morgan Beats Q3 Earnings Estimates, Improves Leverage
    Finance
    Market Realist

    Kinder Morgan Beats Q3 Earnings Estimates, Improves Leverage

    Kinder Morgan Beats Q3 Earnings Estimates, Improves Leverage Kinder Morgan’s third-quarter results Kinder Morgan (KMI) announced its third-quarter results on October 17 after the markets closed. The company announced an adjusted EPS of $0.21—up ~40%

  • Aurora Cannabis stock leads sector higher after news it will start trading on NYSE next week
    News
    MarketWatch

    Aurora Cannabis stock leads sector higher after news it will start trading on NYSE next week

    Canadian marijuana company Aurora Cannabis Inc.’s shares rose about 4% Thursday after it said shares have been approved for trading on the New York Stock Exchange starting October 23. The stock (CA:ACB)(CA:ACB) which is currently trading on the over-the-counter market, will trade under the ticker symbol “ACB”. The shares are also traded on the Toronto Stock Exchange.

  • Finance
    Investopedia

    Berkshire Is Undervalued, Says JPMorgan

    Berkshire Hathaway Inc.'s ( BRK.B) Class B shares are cheap if you apply the same metrics that its CEO Warren Buffett does to value companies, according to JPMorgan. In a research note, reported on by CNBC, analyst Sarah DeWitt said Berkshire, a company that investors have historically struggled to value properly because of its many moving parts, suddenly appears to be attractively priced when factoring in all the profits made by the stocks held in its $200 billion equity portfolio into its earnings. “Look-through earnings” take into account current period earnings that show up in financial statements, together with other sources of earnings expected in the long run. This method is used by Buffett as a way to appreciate that companies sometimes retain earnings after paying dividends and later invest them at a higher rate of return.